Stocks
Ceryvyn Therapeutics LtdOPTEY
PNKHealthcareBiotechnology$0.03
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for inflammatory and autoimmune diseases, with a focus on oral small molecules targeting the JAK pathway. Its lead candidate, Cevidoplenib, is in Phase 2 trials for chronic spontaneous urticaria and other indications. Investors track the company for its potential in the dermatology and immunology markets.
52W Range: $0.00-$3.41
Congressional Interest in Ceryvyn Therapeutics Ltd (OPTEY)
No congressional trades have been disclosed for Ceryvyn Therapeutics Ltd (OPTEY) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading OPTEY?
No congressional trades found for this stock.